The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases

Clinical Immunology

Volumn 175, Issue , 2017, Pages 10-15

  Mao Draayer, Yang ^a   Sarazin, Jeffrey ^a   Fox, David ^a   Schiopu, Elena ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SIPONIMOD; SPHINGOSINE 1 PHOSPHATE RECEPTOR; LYSOPHOSPHOLIPID; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CLINICAL FEATURE; DERMATOMYOSITIS; DRUG TARGETING; HUMAN; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; MYOSITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYMYOSITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; ANALOGS AND DERIVATIVES; ANIMAL; CENTRAL NERVOUS SYSTEM; METABOLISM;

ANIMALS; AUTOIMMUNE DISEASES; CENTRAL NERVOUS SYSTEM; HUMANS; LYSOPHOSPHOLIPIDS; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE;

EID: 84999280602     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2016.11.008     Document Type: Review

References (62)

1. [1] Magliozzi, R., et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130 (2007), 1089–1104, 10.1093/brain/awm038.
2. [2] Weiner, H.L., A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J. Neurol. 255:Suppl. 1 (2008), 3–11, 10.1007/s00415-008-1002-8.
3. [3] Quintana, F.J., et al. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 18889–18894, 10.1073/pnas.0806310105.
4. [4] Stadelmann, C., Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implications. Curr. Opin. Neurol. 24 (2011), 224–229, 10.1097/WCO.0b013e328346056f.
5. [5] Dutta, R., Trapp, B.D., Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog. Neurobiol. 93 (2011), 1–12, 10.1016/j.pneurobio.2010.09.005.
6. [6] Hunter, S.F., et al. The direct effects of fingolimod in the central nervous system: implications for relapsing multiple sclerosis. CNS Drugs 30 (2016), 135–147, 10.1007/s40263-015-0297-0.
7. [7] Groves, A., Kihara, Y., Chun, J., Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J. Neurol. Sci. 328:0 (2013), 9–18, 10.1016/j.jns.2013.02.011.
8. [8] Tullman, M.J., Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. Am. J. Manag. Care(Suppl. 2), 2013, S15–S20.
9. [9] Goodin, D.S., et al. Disease modifying therapies in multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58 (2002), 169–178, 10.1212/WNL.58.2.169: 1526-632X.
10. [10] Kappos, L., et al. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. Neurology 57 (2001), 1969–1975, 10.1212/WNL.57.11.1969: 1526-632X.
11. [11] Panitch, H., Miller, A., Paty, D., Weinshenker, B., Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 63 (2004), 1788–1795, 10.1212/01.WNL.0000146958.77317.3E: 1526-632X.
12. [12] Cohen, J.A., et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362 (2010), 402–415, 10.1056/NEJMoa0907839.
13. [13] Kappos, L., et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 355 (2006), 1124–1140, 10.1056/NEJMoa052643.
14. [14] Kappos, L., et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362 (2010), 387–401, 10.1056/NEJMoa0909494.
15. [15] Hla, T., Physiological and pathological actions of sphingosine 1-phosphate. Semin. Cell Dev. Biol. 15 (2004), 513–520, 10.1016/j.semcdb.2004.05.002.
16. [16] Brinkmann, V., et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 277 (2002), 21453–21457, 10.1074/jbc.C200176200.
17. [17] Paugh, S.W., Payne, S.G., Barbour, S.E., Milstien, S., Spiegel, S., The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett. 554 (2003), 189–193, 10.1016/S0014-5793(03)01168-2.
18. [18] Rosen, H., Gonzalez-Cabrera, P.J., Sanna, M.G., Brown, S., Sphingosine 1-phosphate receptor signaling. Annu. Rev. Biochem. 78 (2009), 743–768, 10.1146/annurev.biochem.78.072407.103733.
19. [19] Rosen, H., Goetzl, E.J., Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat. Rev. Immunol. 5 (2005), 560–570, 10.1038/nri1650.
20. [20] Walzer, T., et al. Natural killer cell trafficking in vivo requires a dedicated sphingosine 1- phosphate receptor. Nat. Immunol. 8 (2007), 1337–1344, 10.1038/ni1523.
21. [21] Groves, A., Kihara, Y., Chun, J., Fingolimod: direct CNS effects of sphingosine 1- phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J. Neurol. Sci. 328 (2013), 9–18, 10.1016/j.jns.2013.02.011.
22. [22] Bar-Or, A., The immunology of multiple sclerosis. Semin. Neurol. 28 (2008), 29–45, 10.1055/s-2007-1019124.
23. [23] Matloubian, M., et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427 (2004), 355–360, 10.1038/nature02284.
24. [24] Graler, M.H., Goetzl, E.J., The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J. 18 (2004), 551–553, 10.1096/fj.03-0910fje.
25. [25] Chiba, K., et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J. Immunol. 160 (1998), 5037–5044 (ISSN: 1550-6606).
26. [26] Cohen, J.A., et al. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 15:4 (April 2016), 373–381, 10.1016/S1474-4422(16)00018-1.
27. [27] Kappos, L., Arnold, D.L., Bar-Or, A., Camm, J., Derfuss, T., Kieseier, B.C., Sprenger, T., Greenough, K., Ni, P., Harada, T., Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 15:11 (October 2016), 1148–1159, 10.1016/S1474-4422(16)30192-2.
28. [28] Gergely, P., et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br. J. Pharmacol. 167 (2012), 1035–1047, 10.1111/j.1476-5381.2012.02061.x.
29. [29] Lewis, N.D., et al. Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3. J. Immunol. 190 (2013), 3533–3540, 10.4049/jimmunol.1201810.
30. [30] Chiba, K., Adachi, K., Sphingosine 1-phosphate receptor 1 as a useful target for treatment of multiple sclerosis. Pharmaceuticals 5:5 (2012), 514–528, 10.3390/ph5050514.
31. [31] O'Sullivan, C., et al. The dual S1PR1/S1PR5 drug BAF312 (siponimod) attenuates demyelination in organotypic slice cultures. J. Neuroinflammation, 13, 2016, 31, 10.1186/s12974-016-0494-x.
32. [32] Terai, K., et al. Edg-8 receptors are preferentially expressed in oligodendrocyte lineage cells of the rat CNS. Neuroscience 116 (2003), 1053–1062, 10.1016/S0306-4522(02)00791-1.
33. [33] Novgorodov, A.S., El-Alwani, M., Bielawski, J., Obeid, L.M., Gudz, T.I., Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration. FASEB J. 21 (2007), 1503–1514, 10.1096/fj.06-7420com.
34. [34] Jaillard, C., Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J. Neurosci. 25 (2005), 1459–1469, 10.1523/JNEUROSCI.4645-04.2005.
35. [35] Jung, C.G., et al. Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia 55 (2007), 1656–1667, 10.1002/glia.20576.
36. [36] Yu, N., Lariosa-Willingham, K.D., Lin, F.F., Webb, M., Rao, T.S., Characterization of lysophosphatidic acid and sphingosine-1-phosphate-mediated signal transduction in rat cortical oligodendrocytes. Glia 45 (2004), 17–27, 10.1002/glia.10297.
37. [37] McGiffert, C., Contos, J.J., Friedman, B., Chun, J., Embryonic brain expression analysis of lysophospholipid receptor genes suggests roles for s1p(1) in neurogenesis and s1p(1-3) in angiogenesis. FEBS Lett. 531 (2002), 103–108, 10.1016/S0014-5793(02)03404-X.
38. [38] Harada, J., Foley, M., Moskowitz, M.A., Waeber, C., Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells. J. Neurochem. 88 (2004), 1026–1039, 10.1046/j.1471-4159.2003.02219.x.
39. [39] Kajimoto, T., et al. Involvement of sphingosine-1-phosphate in glutamate secretion in hippocampal neurons. Mol. Cell. Biol. 27 (2007), 3429–3440, 10.1128/MCB.01465-06.
40. [40] Mizugishi, K., et al. Essential role for sphingosine kinases in neural and vascular development. Mol. Cell. Biol. 25 (2005), 11113–11121, 10.1128/MCB.25.24.11113-11121.2005.
41. [41] Edsall, L.C., Pirianov, G.G., Spiegel, S., Involvement of sphingosine 1-phosphate in nerve growth factor-mediated neuronal survival and differentiation. J. Neurosci. 17 (1997), 6952–6960.
42. [42] Toman, R.E., et al. Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension. J. Cell Biol. 166 (2004), 381–392, 10.1083/jcb.200402016.
43. [43] Di Menna, L., et al. Fingolimod protects cultured cortical neurons against excitotoxic death. Pharmacol. Res. 67 (2013), 1–9, 10.1016/j.phrs.2012.10.004.
44. [44] Zhang, Y.H., Vasko, M.R., Nicol, G.D., Intracellular sphingosine 1-phosphate mediates the increased excitability produced by nerve growth factor in rat sensory neurons. J. Physiol. 575 (2006), 101–113, 10.1113/jphysiol.2006.111575.
45. [45] Kappos, L., Efficacy and safety of siponimod in secondary progressive multiple sclerosis - Results of the placebo controlled, double-blind, Phase III EXPAND study. Oral presentation presented at: 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; September, 2016, 14–17 London, UK.
46. [46] Tsunemi, S., Iwasaki, T., Kitano, S., Imado, T., Miyazawa, K., Sano, H., Effects of the novel immunosuppressant FTY720 in a murine rheumatoid arthritis model. Clin. Immunol. 136 (2010), 197–204, 10.1016/j.clim.2010.03.428.
47. [47] Danko, K., Vencovsky, J., Lundberg, I.E., Amato, A.A., Oddis, C.V., Molnar, M., Moher, A.M., Colin, L., Muellershausen, F., Lee, D., Gergely, P., The selective sphingosine-1- phosphate receptor 1/5 modulator siponimod (BAF312) shows beneficial effects in patients with active, treatment refractory polymyositis and dermatomyositis: a phase IIa proof-of-concept, double-blind, randomized trial. Arthritis Rheum., 910(Supp 10), 2014, S403, 10.1002/art.38914.
48. [48] McInnes, I.B., O'Dell, J.R., State-of-the-art: rheumatoid arthritis. Ann. Rheum. Dis. 69 (2010), 1898–1906, 10.1136/ard.2010.134684.
49. [49] Zhao, C., Fernandes, M.J., Turgeon, M., Tancrede, S., Di Battista, J., Poubelle, P.E., Bourgoin, S.G., Specific and overlapping sphingosine-1-phosphate receptor functions in human synoviocytes: impact of TNF-alpha. J. Lipid Res. 49 (2008), 2323–2337, 10.1194/jlr.M800143-JLR200.
50. [50] Schwab, S.R., et al. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 309 (2005), 1735–1739, 10.1126/science.1113640.
51. [51] Fleischmann, R.M., et al. The oral S1P lyase inhibitor LX3305 (LX2931) demonstrates favorable safety and potential clinical benefit at 12-weeks in a phase 2 proof-of- concept trial in patients with active rheumatoid arthritis on stable methotrexate therapy. Arthritis Rheum., 910(Supp 10), 2011, S1018, 10.1002/art.33310.
52. [52] Felson, D.T., Anderson, J.J., Boers, M., Bombardier, C., Furst, D., Goldsmith, C., Katz, L.M., Lightfoot, R., Paulus, H., Strand, V., Tugwell, P., Weinblatt, M., James Williams, H., Wolfe, F., Kieszak, S., American college of rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38 (1995), 727–735, 10.1002/art.1780380602.
53. [53] Clark, D.N., Markham, J.L., Sloan, C.S., Poole, B.D., Cytokine inhibition as a strategy for treating systemic lupus erythematosus. Clin. Immunol. 148:3 (September 2013), 335–343, 10.1016/j.clim.2012.11.001.
54. [54] Gottschalk, T.A., Tsantikos, E., Hibbs, M.L., Pathogenic inflammation and its therapeutic targeting in systemic lupus erythematosus. Front. Immunol., 6, 2015, 550, 10.3389/fimmu.2015.00550.
55. [55] Moulton, V.R., Tsokos, G.C., Abnormalities of T cell signaling in systemic lupus erythematosus. Arthritis Res. Ther., 13(2), 2011, 207, 10.1186/ar3251.
56. [56] Wardemann, H., Nussenzweig, M.C., B-cell self-tolerance in humans. Advances in Immunology, 95, 2007, Academic Press, 83–110.
57. [57] Milisenda, J.C., Selva-O'Callaghan, A., Grau, J.M., The diagnosis and classification of polymyositis. J. Autoimmun. 48–49 (February–March 2014), 118–121, 10.1016/j.jaut.2014.01.025.
58. [58] Dalakas, M.C., Hohlfeld, R., Polymyositis and dermatomyositis. Lancet 362:9388 (20 September 2003), 971–982, 10.1016/S0140-6736(03)14368-1.
59. [59] Mammen, A.L., Dermatomyositis and polymyositis. Ann. N. Y. Acad. Sci. 1184 (2010), 134–153, 10.1111/j.1749-6632.2009.05119.x.
60. [60] Gonzalez-Cabrera, P.J., et al. S1P signaling: new therapies and opportunities. F1000 Prime Reports, 6, 2014, 109, 10.12703/P6-109.
61. [61] Zhang, Z., Zhao, C., Sphingosine-1-phosphate and rheumatoid arthritis: pathological implications and potential therapeutic targets. Matsuno, H., (eds.) Innovative Rheumatology, 2013, InTech, 10.5772/53308.
62. [62] Yang, Z., Chen, M., Fialkow, L.B., Ellett, J.D., Wu, R., Brinkmann, V., Nadler, J.L., Lynch, K.R., The immune modulator FYT720 prevents autoimmune diabetes in nonobese diabetic mice☆. Clin. Immunol. 107:1 (April 2003), 30–35, 10.1016/S1521-6616(02)00054-2.